The Wegener’s Granulomatosis Treatment Market trends reflect a fundamental movement away from non-specific immunosuppression toward targeted biologic and small molecule therapies. The most significant trend is the increasing use of Rituximab as the preferred induction therapy in non-inferiority trials, marking a paradigm shift away from cyclophosphamide for many patients. This...